Regeneron Q1 Beats on Revenue and EPS as Pipeline Milestones Accumulate

Transcript intelligence

What changed

Revenue growth accelerated sharply from 3% in Q4 2025 to 19% in Q1 2026. Several pipeline milestones landed this quarter that were not present in the prior report: Otarmeni received FDA approval, cemdisiran posted positive Phase III data, and olatorepatide advanced toward global Phase III. New capital-return and policy actions emerged, including a $3 billion buyback authorization and a Most-Favored-Nation pricing agreement with the U.S. government. New collaborations with Telix and TriNetX were disclosed. On the negative side, GAAP gross-margin guidance was lowered from 83-84% to 77-78% due to a temporary manufacturing interruption in Ireland, and the EYLEA HD prefilled-syringe PDUFA date was missed with a re-inspection now completed.

Guidance delta

Management adjusted only the GAAP gross-margin range to 77-78%, down from the 83-84% introduced with full-year 2026 guidance in Q4 2025, citing a temporary manufacturing interruption at the Limerick, Ireland facility. The overall revenue and operating-expense outlook was maintained. Guidance sentiment remains 'maintained.'

Key takeaways

• Q1 revenue rose 19% YoY to $3.6B with non-GAAP EPS up 15%, beating consensus on both lines (EPS $9.47 vs $8.91 est; revenue $3.61B vs $3.48B est).
• DUPIXENT sales accelerated with double-digit growth; EYLEA HD surged 52%; Libtayo contributed solid performance.
• Otarmeni, a gene therapy for genetic hearing loss, received FDA approval and is being offered free in the U.S.
• Cemdisiran (C5 siRNA) posted positive Phase III data in generalized myasthenia gravis, showing superior efficacy to existing C5 inhibitors.
• A $3 billion share-repurchase program was authorized, and a Most-Favored-Nation pricing agreement was reached with the U.S. government.
• GAAP gross-margin guidance was cut to 77-78% from 83-84% due to the Ireland manufacturing disruption; the rest of the outlook was maintained.

Management priorities

• Expand DUPIXENT into new indications, age groups, and geographic markets.
• Advance olatorepatide into global Phase III programs for obesity and Type 2 diabetes.
• Resolve the EYLEA HD prefilled-syringe regulatory timeline (re-inspection completed, decision expected this quarter).
• Seek FDA approval for garetosmab (priority review decision expected August 2026).
• Initiate the first-in-human trial of an IL-13 antibody by mid-year.
• Advance next-generation IL-4/IL-13 bispecifics targeting the DUPIXENT pathway.